Phase II (NAVIGATE-AD study) Results of LY3202626 Effects on Patients with Mild Alzheimer's Disease Dementia.

JAD Reports
Albert C LoBrian A Willis

Abstract

LY3202626 is a small molecule inhibitor of β-site amyloid precursor protein cleaving enzyme (BACE)1 shown to reduce amyloid-β (Aβ)1-40 and Aβ1-42 concentrations in plasma and cerebrospinal fluid developed for the treatment of Alzheimer's disease (AD). To assess the change from baseline in flortaucipir positron emission tomography (PET) after treatment with LY3202626 compared with placebo in patients with mild AD dementia. Patients received daily 3 mg or 12 mg doses of LY3202626 or placebo for 52 weeks. The primary outcome was assessment of cerebral neurofibrillary tangle load by flortaucipir PET. The study was terminated early following an interim analysis due to a low probability of identifying a statistically significant slowing of cognitive and/or functional decline. A total of 316 patients were randomized and 47 completed the study. There was no statistically significant difference between placebo and either dose of LY3202626 from baseline to 52 weeks, or in annualized change for flortaucipir PET. There was no clinically meaningful difference between placebo and LY3202626 doses on efficacy measures of cognition and function. No deaths or serious adverse events considered related to LY3202626 were reported. A statistically s...Continue Reading

References

Nov 1, 1975·Journal of Psychiatric Research·M F FolsteinP R McHugh
Aug 21, 2003·Progress in Neurobiology·Paul R TurnerWickliffe C Abraham
Jun 24, 2004·Journal of the American Geriatrics Society·Douglas GalaskoPierre N Tariot
Apr 9, 2005·Journal of the American Geriatrics Society·Ziad S NasreddineHoward Chertkow
Jul 2, 2008·Neuropsychology·Sarah Tomaszewski FariasCharles Decarli
Jan 29, 2010·The New England Journal of Medicine·Henry W Querfurth, Frank M LaFerla
Jan 24, 2012·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Bradley T HymanThomas J Montine
Jan 25, 2012·European Journal of Nuclear Medicine and Molecular Imaging·Ing-Tsung HsiaoKun-Ju Lin
Feb 16, 2013·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Chun-Fang XiaHartmuth C Kolb
Aug 21, 2013·Journal of Alzheimer's Disease : JAD·David T ChienHartmuth C Kolb
Mar 22, 2014·Science Translational Medicine·Reisa A SperlingPaul Aisen
Jan 21, 2015·Biological Psychiatry·Severin FilserJochen Herms
May 14, 2016·Science Translational Medicine·Matthew R BrierBeau M Ances
May 3, 2018·The New England Journal of Medicine·Michael F EganDavid Michelson
May 22, 2018·Alzheimer's & Dementia : Diagnosis, Assessment & Disease Monitoring·Adam J SchwarzUNKNOWN Alzheimer's Disease Neuroimaging Initiative
Jun 28, 2018·Biological Psychiatry·Kaichuan ZhuJochen Herms
Aug 11, 2018·Frontiers in Aging Neuroscience·Tanja BlumeJochen Herms
Apr 11, 2019·The New England Journal of Medicine·Michael F EganDavid Michelson
Apr 11, 2019·The New England Journal of Medicine·David HenleyGary Romano
May 28, 2020·Alzheimer's Research & Therapy·Tugce Munise SatirHenrik Zetterberg

❮ Previous
Next ❯

Citations

Jun 4, 2021·Journal of Medicinal Chemistry·David L McKinzieDustin J Mergott
Aug 8, 2021·International Journal of Molecular Sciences·Tien-Wei YuChieh-Hsin Lin

❮ Previous
Next ❯

Software Mentioned

Perl
FreeSurfer
NONMEM
FISHER
NAVIGATE
AD
Pirana

Related Concepts

Related Feeds

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

CSF & Lymphatic System

This feed focuses on Cerebral Spinal Fluid (CSF) and the lymphatic system. Discover the latest papers using imaging techniques to track CSF outflow into the lymphatic system in animal models.

Alzheimer's Disease: Neuroimaging

Neuroimaging can help identify pathological hallmarks of Alzheimer's disease (AD). Here is the latest research on neuroimaging modalities, including magnetic resonance imaging and positron emission tomography, in AD.